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Statins increase peroxisome proliferator-activated receptor α (PPARα) mRNA expression, but the mechanism of this increased
PPARα production remains elusive. To examine the regulation of PPARα production, we examined the eﬀect of 7 statins
(atorvastatin,cerivastatin,ﬂuvastatin,pitavastatin,pravastatin,rosuvastatin,andsimvastatin)onhumanPPARαpromoteractivity,
mRNA expression, nuclear protein levels, and transcriptional activity. The main results are as follows. (1) Majority of statins
enhancedPPARαpromoteractivityinadose-dependentmannerinHepG2cellstransfectedwiththehumanPPARαpromoter.This
enhancement may be mediated by statin-induced HNF-4α.( 2 )P P A R α mRNA expression was increased by statin treatment. (3)
The PPARα levels in nuclear fractions were increased by statin treatment. (4) Simvastatin, pravastatin, and cerivastatin markedly
enhancedtranscriptionalactivityin293Tcellscotransfectedwithacyl-coenzymeAoxidasepromoterandPPARα/RXRαexpression
vectors. In summary, these data demonstrate that PPARα production and activation are upregulated through the PPARα promoter
activity by statin treatment.
Copyright © 2008 Makoto Seo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, are the most widely used drugs
to lower low-density lipoprotein (LDL) cholesterol. These
mechanisms have been reported that treatment with statins
results in lowering intracellular cholesterol concentration,
and then increasing a proteolytic activation of sterol
responsive element-binding proteins (SREBPs) [1]. These
transcription factors increase the cholesterol homeostasis
controlling genes, such as LDL receptor, lipoprotein lipase,
and cholesterol 7α-hydroxylase [2, 3].
Currently, statins are the ﬁrst choice of therapeutic agent
for the treatment of hyperlipidemia. Several mega trials and
large cohort studies using statins have shown that statins
prevent coronary heart disease and decrease the incidence of
cardiovascular events [4–6]. The reasons why cardiovascular
events were decreased with statins are reported to be due
to many pleiotropic eﬀects, for example, inhibition of the
proliferation and migration of endothelial cells, smooth
muscle cells, and macrophages [7, 8]. Moreover, statins up-
regulate the expression of endothelial nitric oxide synthesis
[9] and suppress oxidative stress, as seen in the reduced
formation of reactive oxygen species and p22phox expression
[10, 11].
T h epe r o x i s o m ep r o l i f e ra t o r - a cti v a t e dr e c e p t o r s( P P A R s )
belong to the nuclear receptor superfamily and play an
important role in the regulation of lipid and glucose
metabolism and adipocyte diﬀerentiation [12, 13]. PPARα
is expressed in the liver, kidney, heart, and muscle where it
regulates energy homeostasis. PPARα forms a heterodimer
with retinoid X receptor α (RXR α), which enhances
its binding to peroxisome proliferator response elements
(PPREs) and activates target genes. PPARα activates the
uptake and catabolism of fatty acids that result in a decrease
of triglyceride (TG), stimulate gluconeogenesis, and enhance
high-density lipoprotein synthesis [14, 15]. Fibrates, which
are a ligand for PPARα, have been reported to lower the2 PPAR Research
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Figure 1: Time-course of PPARα mRNA expression in HepG2 cells
after treatment with 10μM simvastatin. The data are expressed as
% of controls at 0 hour. Values are presented as the mean ± SEM
of three separate experiments, signiﬁcantly diﬀerent from control
at ∗P<. 05, ∗∗P<. 01.
serum TG levels [16]. Some statins were also reported
to decrease the serum TG levels to same extent [17–
19]. Although it is reported that several statins increase
PPARα [20, 21], it is not clear how statins regulate nuclear
transcription, and PPARα mRNA expression and activity.
Previously, simvastatin activated mouse PPARα promoter
and induced the transcription of PPARα gene [22], but there
is no report that statins activate the human PPARα promoter
and transcription of this gene.
In the present study, we investigated the eﬀect of 7
statins (atorvastatin, cerivastatin, ﬂuvastatin, pitavastatin,
pravastatin, rosuvastatin, simvastatin) on the regulation of
PPARα mRNA expression and PPARα protein levels in
nuclear fraction of the human hepatoblastoma cell line
(HepG2 cells). We also investigated the eﬀect of statin
treatment on the promoter activity of the human PPARα
gene. In addition, we investigated whether statin treatment
could induce transcriptional activity of PPARα.
2. MATERIALS AND METHODS
2.1. Reagentsandcellculture
Seven statins were kindly provided as follows; atorvastain
(Warner-Lambert Co., Ltd.), cerivastatin (Bayel Co., Ltd.),
ﬂuvastatin (Novartis Co., Ltd.), pitavastatin (Kowa Co.,
Ltd.), pravastatin (Sankyo Co., Ltd.), and rosuvastatin
(AstraZeneca Ltd.). Simvastatin was purchased from Wako
Pure Chemical Industries, Ltd. (Tokyo, Japan). Fenoﬁbric
acid (FA) was kindly provided by Kaken Pharmaceutical
Co., Ltd. Atorvastatin, cerivastatin, ﬂuvastatin, pitavastatin,
rosuvastatin, and FA were dissolved in dimethyl sulfoxide
(DMSO); simvastatin was dissolved in ethanol, and pravas-
tatin was dissolved in distilled water. In all assays, the
ﬁnal concentrations of DMSO and ethanol were less than
0.5%. HepG2 cells was purchased from JCRB (cell number:
JCRB1054) and human kidney 293T cells (293T cells) from
Dainippon Pharmaceutical Co., Ltd. They were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Invitrogen)
containing 10% heat-inactivated fetal bovine serum (FBS)
(JRH Biosciences) and PNS antibiotic mixture (Invitrogen)
at 37
◦Ci n5 %C O 2.
2.2. CloningofthePPARαpromoterand
plasmidconstructions
To generate human PPARα promoter-reporter plasmid, we
referred to the genomic sequence that has been reported pre-
viously [23]. Human PPARα promoter containing −1553 bp
to +88bp was obtained by polymerase chain reaction (PCR)
with human genomic DNA (Clontech) using a forward
primer 5 -CATAAGCTTACCCCACGAGATATGCAGGAT-3 
(including a Hind III site, underlined) and a reverse
primer 5 -CGTAAGCTTCGCAAGAGTCCTCGGTGTGT-3 
(including a Hind III site, underlined). This promoter
was cloned into the Hind III site of a pGL3-Basic vector
(Promega).Plasmid DNA used for transfectionwasprepared
using the Wizard Plus Minipreps DNA Puriﬁcation System
(Promega). Nucleotide sequences of this plasmid were
conﬁrmed by sequencing using ABI PRISM 310 Genetic
Analyzer (Applied Biosystems).
2.3. LuciferaseassayofPPARαpromoteractivity
HepG2 cells were transfected using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocols. The
cells(1×105 cells/well)wereseededin24-wellplates(Falcon)
and incubated for 18 hours before transfection. The cells
were transfected with the use of Lipofectamine 2000 with
1μg of human PPARα promoter-reporter plasmid and 0.1μg
of pRL-TK (Promega), a renilla luciferase reporter vector as
internal control for transfection eﬃciency. After 3 hours, the
transfection medium was replaced by 10% FBS-DMEM plus
the various amounts of statin (0, 1, 10, 25, and 50μM) or
vehicle(DMSO,ethanol,ordistilledwater)andthecellswere
incubated for 24 hours. Luciferase activities were quantiﬁed
using a Dual-Luciferase Reporter Assay System (Promega)
according to the manufacturer’s protocols.
2.4. Real-timereversetranscription(RT)-PCRanalysis
HepG2 cells (2 × 105 cells/dish) were incubated with
various amounts of statin (0, 5, 10, and 20μM, pravastatin
was 50, 100, and 250μM) at 37
◦C for 24 hours. After
treatment with statins, cells were homogenized in 1mL of
ISOGEN (Nippongene), and then total RNA was extracted
with chloroform and precipitated with ethanol. First-strand
cDNA was generated from total RNA with random hexamers
and MuLV transcriptase (Applied Biosystems) according to
the manufacturer’s protocols. PCR reactions were performed
with TaqMan Universal PCR Master Mix and TaqMan
Gene Expression Assays (Applied Biosystems). Identiﬁcation
numbers of the assay mixture of target gene-speciﬁc primers
andprobeswereasfollows:humanPPARα,Hs00231882 m1;
18S ribosomal RNA (house-keeping gene), Hs99999901 s1.Makoto Seo et al. 3
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Figure 2:PPARαmRNAexpressioninHepG2cellsaftertreatmentwithatorvastatin(Ator),cerivastatin(Ceri),ﬂuvastatin(Flu),pitavastatin
(Pita), pravastatin (Pra), rosuvastatin (Rosu), and simvastatin (Sim) for 24 hours. (a) Each statin was used at concentrations of 5, 10, and
20μM. Nontreated cells (statin concentration 0μM) were the control. (b) Pravastatin was used at higher concentrations of 20, 50, 100, and
250μM. Nontreated cells (pravastatin concentration 0μM) were the control. The data are expressed as % of controls. Values are presented
as the mean ± SEM of three separate experiments, signiﬁcantly diﬀerent from control at ∗P<. 05, ∗∗P<. 01.
Real-time PCR reactions were performed with thermal
cycling conditions of 2 minutes at 50
◦C, 10 minutes at
95
◦C ,a n d4 0c y c l e so f1 5s e c o n d sa t9 5
◦C and 1 minute at
60
◦C using ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems). PPARα mRNA levels were normalized
to 18S ribosomal RNA levels, and are presented as fold
diﬀerence of statin-treated cells compared with untreated
cells.
2.5. Westernblotanalysis
HepG2 cells (2 × 105 cells/dish) were seeded in 60mm
dishes (Falcon) and incubated for 18 hours. Then, the
cells were incubated with 10 and 25μM statin at 37
◦Cf o r
24 hours. After treatment with statins, cells were washed
with ice-cold phosphate buﬀered saline and collected. After
centrifugation (15,000×g), the cytoplasmic and nuclear
proteins of the cells were extracted with NE-PER Nuclear
andCytoplasmicExtractionReagents(PIERCE)accordingto
the manufacturer’s protocols and the proteins concentration
was determined with a BCA Protein Assay kit (PIERCE).
Aliquots(15μg)ofcytoplasmicornuclearproteinswereelec-
trophoresed on 9% sodium dodecyl sulfate-polyacrylamide
gels and transferred to polyvinylidene diﬂuoride membranes
(Millipore).ThemembraneswereblockedwithBlockingOne
(Nacalai Tesque, Inc.), and incubated overnight with goat
anti-PPARα IgG antibody (sc-1985, Santa Cruz) (diluted
1:1000 with BlockingOne) or mouse anti-hepatocyte nuclear
factor-4α (HNF-4α) IgG antibody (Clone no.: H1415,
Perseus Proteomics Co., Ltd.). After washing four times with
Tris-buﬀered saline-containing 0.5% Tween 20, signals from
Western blots were obtained using horseradish peroxidase-
conjugated secondary anti-goat antibody (diluted 1:2000
with BlockingOne) and visualized with the ECL detection
system (Amersham Biosciences). The PPARα protein levels
were quantiﬁed with an imaging analyzer (Densitograph,
ATTO). The data are expressed as % of control.
2.6. LuciferaseassayofPPREactivity
Constructions of pCI-PPARα and pCI-RXRα expression
plasmids were described previously [24]. Brieﬂy, the full-
length human PPARα (GenBank accession no. L 02932)
and human RXRα (GenBank accession no. X 52773) were
prepared by PCR. The speciﬁc DNA fragmant of human
PPARα was cloned into the SalI-NotI sites of the pCI-neo
mammalianexpressionvector(Promega).ThehumanRXRα
was also cloned into the XhoI-NotI sites of the pCI-neo. The
humanacyl-coenzymeAoxidase(AOX)promoter(GenBank
accession no. NT 010641) construct containing the PPREs
waspreviouslyclonedintotheKpnI-NcoI sitesofpGL3-Basic
vector [25].
To measure the transcriptional activation of PPRE,
293T cells (0.5 × 105 cells/well) were seeded in collagen
type I-coated 24-well plate (Iwaki) and incubated for 18
hours before transfection. The cells were transfected using
Lipofectamine 2000 with 0.5μgo fh u m a nA O Xp r o m o t e r -
reporter plasmid, 0.1μg of pRL-TK as internal control for
transfection eﬃciency and either 0.25μg of pCI-PPARα and
pCI-RXRα expression vectors or 0.5μg of pCI-neo vector.
After 3 hours, the transfection medium was replaced by 10%
FBS-DMEM plus the various amounts of statin (0, 1, 10,
25, and 50μM), fenoﬁbric acid (0, 1, 10, 50, 100μM), or
vehicle(DMSO,ethanol,ordistilledwater)andthecellswere
incubated for 24 hours. Luciferase activities were quantiﬁed
using a Dual-Luciferase Reporter Assay System (Promega)
according to the manufacturer’s protocols.Makoto Seo et al. 5
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Figure 3: PPARα promoter activity in HepG2 cells transfected with human PPARα promoter-reporter plasmid after treatment with
atorvastatin (Ator), cerivastatin (Ceri), ﬂuvastatin (Flu), pitavastatin (Pita), pravastatin (Pra), rosuvastatin (Rosu), and simvastatin (Sim)
for 24 hours. Each statin was used at doses of 1, 10, 25, and 50μM. Nontreated cells (statin concentration 0μM )w e r et h ec o n t r o l .T h ed a t a
are expressed as % of controls. Values are presented as the mean ± SEM of three separate experiments, signiﬁcantly diﬀerent from control at
∗P<. 05, ∗∗P<. 01.6 PPAR Research
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Figure 4: The Western blots represent PPARα protein levels in nuclear fractions of HepG2 cells after treatment with 10μM (a) and 25μM
(b) of statin for 24 hours (Cont., control; Ator, atorvastatin; Ceri, cerivastatin; Flu, ﬂuvastatin; Pita, pitavastatin; Pra, pravastatin; Rosu,
rosuvastatin; Sim, simvastatin). The PPARα protein levels were quantiﬁed with an imaging analyzer. The data are expressed as % of control.
Values are presented as the mean ± SEM of three separate experiments, signiﬁcantly diﬀerent from control at ∗P<. 05, ∗∗P<. 01.
2.7. Statisticalanalysis
All data are presented as the means ± SEM. Statistical
analysis was performed using ANOVA followed by the
Dunnett test or Scheﬀe test (StatView software). Statistical
signiﬁcance was considered as P<. 05.
3. RESULTS
3.1. StatinsincreasedPPARαmRNAexpressionin
HepG2cells
We ﬁrst examined the eﬀect of simvastatin on the PPARα
mRNA expression in HepG2 cells. The time-course study
for the PPARα mRNA expression in HepG2 cells treated
with 10μM simvastatin is shown in Figure 1. Simvastatin
signiﬁcantly increased PPARα mRNA expression by 2.0-fold
(versus the control) at 12 and 24 hours.
We next examined the eﬀect of atorvastatin, cerivas-
tatin, ﬂuvastatin, pitavastatin, pravastatin, rosuvastatin, and
simvastatin for 24 hours on PPARα mRNA expression in
HepG2 cells. PPARα mRNA expression following treatment
of HepG2 cells with various amounts of statin is shown in
Figure 2.InFigure 2(a),atorvastatin(20μM),cerivastatin(5,
10, and 20μM), ﬂuvastatin (5, 10, and 20μM), pitavastatin
(20μM), rosuvastatin (10μM), and simvastatin (10μM) sig-
niﬁcantly increased PPARα mRNA expression by more than
1.5-fold (versus the control). Pravastatin did not increase
PPARα mRNA expression at these concentrations, but the
higher concentrations of pravastatin-treatment (100 and
250μM) signiﬁcantly increased PPARα mRNA expression
(Figure 2(b)).
3.2. StatinsincreasedhumanPPARαpromoteractivity
To investigate the mechanism by which statins increase
PPARα mRNA expression, we cloned the human PPARα
promoter region (−1553 to +88bp) and examined promoter
activity in HepG2 cells transfected with the human PPARα
promoter-reporter plasmid. Figure 3 shows the PPARα pro-
moter activity following treatment of HepG2 cells with vari-
ous amounts of statin for 24 hours. Except for pravastatin,
6 statins signiﬁcantly increased PPARα promoter activity
in a dose-dependent manner. Atorvastatin, cerivastatin,
ﬂuvastatin, rosuvastatin, and simvastatin increased PPARα
promoter activity by more than 1.5-fold (versus the con-
trol). However, pravastatin only slightly increased PPARα
promoter activity that was signiﬁcant only at 10μM.Makoto Seo et al. 7
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Figure 5:ThetranscriptionalactivityofPPARαinHepG2cellstransfectedwithhumanacyl-CoAoxidase(AOX)promoter-reporterplasmid
after treatment with fenoﬁbric acid (FA) and statins for 24 hours. (a) FA was used at doses of 1, 10, 50, and 100μM. Nontreated cells (FA
concentration 0μM) were the control. (b) Atorvastatin (Ator), cerivastatin (Ceri), ﬂuvastatin (Flu), pitavastatin (Pita), pravastatin (Pra),
rosuvastatin (Rosu), and simvastatin (Sim) for 24 hours. Each statin was used at doses of 1, 10, 25, and 50μM. Nontreated cells (statin
concentration 0μM) were the control. The data are expressed as % of control. Values are presented as the mean ± SEM of three separate
experiments, signiﬁcantly diﬀerent from control at ∗P<. 05, ∗∗P<. 01.
3.3. StatinsincreasedPPARαlevelsinnuclearfraction
We next examined the increasing eﬀect of statins on
PPARα protein levels in nuclear fraction of HepG2 cells.
Results are shown in Figure 4.I nan u c l e a rf r a c t i o no f
HepG2 cells treated with 10μM statin, PPARα protein levels
were signiﬁcantly increased by treatment with rosuvastatin
(Figure 4(a)). Moreover, PPARα protein levels were signif-
icantly increased by treatment with 25μM of pitavastatin,
simvastatin, and atorvastatin, and the other statins slightly
increased PPARα protein levels (Figure 4(b)). However, in a
cytoplasmic fraction, PPARα p r o t e i nl ev e l sw e r en o tc h a n g e d
by the treatment with 10 and 25μM statins.
3.4. StatinsincreasedPPARαactivity
We next examined the eﬀect of statins on the transcrip-
tional activity of PPARα in 293T cells transfected with
human AOX promoter-reporter plasmid containing PPREs
region, human PPARα,a n dR X R α expression plasmids. In
Figure 5(a),fenoﬁbricacidthatwasusedasapositivecontrol
increased PPARα activity in a dose-dependent manner. In
Figure 5(b), the treatment with cerivastatin (10μM) and
simvastatin (50μM) signiﬁcantly increased transcriptional
activity of PPARα by more than 1.5-fold (versus the con-
trol). Fluvastatin, pitavastatin, pravastatin, and rosuvastatin
tended to increase transcriptional activity of PPARα by 1.2-
to 1.4-fold (versus the control). However, atorvastatin did
not increase the transcriptional activity of PPARα.
3.5. StatinsincreasedHNF-4αlevelsinnuclearfraction
Next, to elucidate the downstream eﬀects of statins on
transcriptional activation by PPARα,w ed e t e c t e dH N F - 4 α
levels in nuclear fraction of HepG2 cells treated with statins
by the use of Western blot analysis. Results are shown in
Figure 6.A t1 0μM statin treatment, ﬂuvastatin, pravastatin,
and rosuvastatin signiﬁcantly increased HNF-4α levels in
nuclear fraction (Figure 6(a)). Moreover, at 25μM statin
treatment, except for cerivastatin, 6 statins signiﬁcantly
increased HNF-4α levels in nuclear fraction (Figure 6(b)).
4. DISCUSSION
The main ﬁndings of the present study were (1) most
statins increased PPARα mRNA expression, which might
be caused via PPARα promoter activation, (2) atorvastatin,
pitavastatin, and simvastatin signiﬁcantly increased PPARα
protein levels in nuclear fraction, (3) some, not but all,
statins interacted with AOX promoter containing PPRE and
increased PPARα activity, and (4) the PPARα promoter
activity could be regulated by the increase of statin-induced
HNF-4α.
Statin therapy has been reported to reduce the incidence
of cardiovascular disease risk in patients with the metabolic
syndrome and hyperlipidemia [26], and these beneﬁts have
been regarded to mainly derive from their lipid-lowering
eﬀect. However, recent studies have suggested that there
are additional, beneﬁcial anti-inﬂammatory eﬀects of stains,
which are independent of their cholesterol-lowering eﬀect
[27, 28]. There are many reports that the anti-inﬂammatory
eﬀects of statins are induced via PPARs signaling-pathway
[11, 29].
Our present results show that most statins increased
PPARα mRNA expression in HepG2 cells after 24 hours
treatment, especially atorvastatin, cerivastatin, ﬂuvastatin,
pitavastatin, rosuvastatin, and simvastatin (more than 1.5-
fold versus control). Statins are classiﬁed into hydrophilic
compounds and lipophilic compounds. In this study, theMakoto Seo et al. 9
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Figure 6:TheWesternblotsrepresentHNF-4αlevelsinnuclearfractionsofHepG2cellsaftertreatmentwithatorvastatin(Ator),cerivastatin
(Ceri), ﬂuvastatin (Flu), pitavastatin (Pita), pravastatin (Pra), rosuvastatin (Rosu), and simvastatin (Sim) for 24 hours. Each statin was used
at doses of 10 (a) or 25 (b) μM. Nontreated cells (statin concentration 0μM) were the control. HNF-4α protein levels were quantiﬁed with an
imaginganalyzer.Thedataareexpressedas%ofcontrol.Valuesarepresentedasthemean ±SEMofthreeseparateexperiments,signiﬁcantly
diﬀerent from control at ∗P<. 05, ∗∗P<. 01.
majority of the statins are lipophilic compounds, but pravas-
tatin and rosuvastatin are hydrophilic compounds. Our
results of PPARα mRNA expression in HepG2 cells treated
with statins show that higher concentrations of pravastatin
(100 and 250μM) signiﬁcantly increased PPARα mRNA
expression.Therefore,inhydrophilicstatin(pravastatin),the
higher concentrations compared with other statins would be
required for increase PPARα mRNA expression.
There are many reports that statins increase PPARα
mRNA expression [11, 21]; however, there are no reports
about the eﬀect of statins on human PPARα promoter activ-
ity.We,therefore,clonedthehumanPPARαpromoterregion
(−1553bp to +88bp) and measured the promoter activity
in HepG2 cells treated with statins. Our present results
show that 6 statins (except for pravastatin) signiﬁcantly
increased PPARα promoter activity in a dose-dependent
manner. Although the eﬀect of statins on mouse PPARα
promoter activity has been reported previously [22], our
present study is the ﬁrst to report the eﬀect of statins on
human PPARα promoter activity.
PPARα promoter region includes many transcription
factor binding domains, such as HNF-4α, PPRE, E-Box,
early growth response factor (Egr-1), and transcription
factor Sp1. HNF-4α is a nuclear receptor that plays a key
role in liver-speciﬁc gene expression. Previously, it was
reported that human PPARα promoter region contains
HNF-4α response element (−1,492bp to −1,483bp), and
HNF-4α induces human PPARα promoter activity [23].
Therefore, we detected HNF-4α levels in nuclear fraction
of statin-treated HepG2 cells. In our present studies, all
statins (25μM) signiﬁcantly increased HNF-4α in nuclear
fractions. This result shows that statins may regulate PPARα
gene transcription mediated by downstream transcriptional
factors (e.g., HNF-4α). Further studies will be necessary
to elucidate molecular mechanisms of statins to regulate
the other transcriptional factors related to PPARα gene
transcription.
Previously, we reported that cerivastatin, ﬂuvastatin,
and simvastatin increased nuclear translocation of PPARα
protein [11]. Our present results show that the 7 statins
utilizedinthepresentstudiesincreasednucleartranslocation
of PPARα p r o t e i ni nH e p G 2c e l l sc o m p a r e dw i t hn o n t r e a t e d
control cells. We next examined the eﬀect of statins on
transcriptional analysis of human AOX promoter in 293T
cells cotransfectedwith human PPARα and RXRα expression
vector. 293T cells were used for these studies expressed very
low levels of endogenous PPARα production when treated
with statins (data not shown). Our present results show that
simvastatin increased human AOX promoter-transcriptional
activity via PPARα/RXRα heterodimer. In fact, we identiﬁed
the upregulation of human AOX mRNA on HepG2 cells and
293T cells treated with statins (data not shown). PPARα is
a ligand-activated transcription factor and is activated by
fatty acid, arachidonic acid [30], and several ﬁbric acids10 PPAR Research
[31]. PPARα-dependent transcriptional activation of many
genes is well documented, and direct, ligand-enhanced inter-
actions between PPARα and the coactivators, p300/cAMP-
response element-binding protein (CREB-) binding protein
(p300/CBP), steroid receptor coactivator-1 (SRC-1), PPAR-
binding protein (PBP), and PPARγ coactivator-1 (PGC-1)
are thought to play a role in PPARα activation [32–34].
The recruitment of speciﬁc coactivators and the release of
corepressors (e.g., nuclear receptor corepressor, NCoR) that
associate with the liganded PPARα/RXRα heterodimer allow
further ﬁne control of gene transcription. PPARα/RXRα het-
erodimer can also bind to PPRE in the unliganded state [35].
The molecular structures of the PPARα/RXRα heterodimeric
complex and coactivators remain to be elucidated. Further
studies will be necessary to be undertaken of the molecular
mechanisms of statin regulation of the gene transcription by
binding to PPREs in the promoter region of target genes.
In conclusion, statins activate PPARα promoter and
then up-regulate PPARα mRNA expression in HepG2 cells.
The eﬀect on PPARα transcription is likely regulated by
various downstream transcriptional factors (e.g., HNF-4α).
Statins increase PPARα p r o t e i nl e v e l si nn u c l e a rf r a c t i o n ,
and moreover, some statins, such as cerivastatin, ﬂuvastatin,
andsimvastatin,signiﬁcantlyactivatethetranscriptionofthe
PPARα target genes.
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